Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCC Warrior Met Coal LLC

Trading 11-02 10:42:12 EST

84.55

-1.42

-1.65%

High86.73	Low82.57	Vol193.03K
Open86.72	D1 Closing85.97	Amplitude4.83%
Mkt Cap4.44B	Tradable Cap4.38B	Total Shares52.57M
T/O16.26M	T/O Rate0.37%	Tradable Shares51.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":84.5525,"timestamp":1793634132528,"preClose":85.97,"halted":0,"volume":193033,"delay":0,"changeRate":-0.016488309875538024,"floatShares":51775204,"shares":52570156,"eps":4.16,"marketStatus":"Trading","change":-1.4175,"latestTime":"11-02 10:42:12 EST","open":86.72,"high":86.725,"low":82.57,"amount":16263721.30814,"amplitude":0.048331,"askPrice":84.88,"askSize":25,"bidPrice":84.47,"bidSize":39,"shortable":3,"etf":0,"ttmEps":4.16,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793653200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":85.97,"dividendRate":0.003785,"preHourTrading":{"tag":"盘前","latestPrice":86.4,"preClose":85.97,"latestTime":"08:31 EST","volume":116,"amount":10000.749759999999,"timestamp":1793626305735,"change":0.43,"changeRate":0.005002,"amplitude":0.010818},"postHourTrading":{"tag":"盘后","latestPrice":85.97,"preClose":85.97,"latestTime":"19:30 EDT","volume":111728,"amount":9605235.34,"timestamp":1793403007562,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.461592,"impliedVol":0.4837,"impliedVolPercentile":0.1673},"requestUrl":"/m/hq/s/HCC/tweets","defaultTab":"tweets","newsList":[{"id":"1104415473","title":"Earning Preview: Warrior Met Coal LLC this quarter’s revenue is expected to increase by 64.20%, and institutional views are Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=1104415473","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1104415473?lang=en_us&edition=fundamental","pubTime":"2026-10-28 21:17","pubTimestamp":1793193461,"startTime":"0","endTime":"0","summary":"Abstract Warrior Met Coal LLC will report fiscal third-quarter results on November 4, 2026 Post-Mkt, and we review consensus expectations for revenue, margins, net profit, and adjusted EPS alongside...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Warrior Met Coal LLC this quarter’s revenue is expected to increase by 64.20%, and institutional views are Neutral","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751720","title":"Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751720?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:00","pubTimestamp":1793620800,"startTime":"0","endTime":"0","summary":"Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/02/3393003/0/en/can-fite-announces-eurasian-patent-allowance-supporting-piclidenoson-development-and-commercialization-in-lowe-syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","BK4081","BK4006","COAL","EMA.AU","EMA","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679966404","title":"Warrior Met Coal Declares Special Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2679966404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679966404?lang=en_us&edition=fundamental","pubTime":"2026-10-29 20:14","pubTimestamp":1793276057,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nFWN46F1MA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679409796","title":"Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2679409796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679409796?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:04","pubTimestamp":1793271840,"startTime":"0","endTime":"0","summary":"SHANGHAI, Oct.  29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/29/3391132/0/en/junshi-biosciences-announces-the-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js207-in-combination-with-js007-for-the-first-line-treatment-of-advanced-hepato.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LU2089985449.USD","ORR","AEIS","HCC","LU0757428866.USD","IE00B19Z4B17.USD","COAL","IE0031619046.USD","BK4006","IE00B66KJ199.SGD","BK4157","LU1815336091.USD","LU2931357623.SGD","BK4195","PFS","LU0274383776.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678143903","title":"Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2678143903","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678143903?lang=en_us&edition=fundamental","pubTime":"2026-10-28 11:48","pubTimestamp":1793159280,"startTime":"0","endTime":"0","summary":"Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/28/3389841/0/en/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","RCC","COAL","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678812814","title":"Warrior Met Coal Keeps Quarterly Dividend at $0.08 a Share, Payable Nov. 13 to Holders of Record Nov. 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2678812814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678812814?lang=en_us&edition=fundamental","pubTime":"2026-10-28 05:52","pubTimestamp":1793137965,"startTime":"0","endTime":"0","summary":"Warrior Met Coal Keeps Quarterly Dividend at $0.08 a Share, Payable Nov. 13 to Holders of Record Nov. 6","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAL","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678485758","title":"Press Release: Warrior Announces Regular Quarterly Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2678485758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678485758?lang=en_us&edition=fundamental","pubTime":"2026-10-28 04:30","pubTimestamp":1793133000,"startTime":"0","endTime":"0","summary":"BROOKWOOD, Ala.--(BUSINESS WIRE)--October 27, 2026--Warrior Met Coal, Inc. (NYSE:HCC) (\"Warrior\" or the \"Company\") today announced that its board of directors has approved a regular quarterly cash div","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678191015","title":"Warrior Met Coal is Maintained at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2678191015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678191015?lang=en_us&edition=fundamental","pubTime":"2026-10-26 22:34","pubTimestamp":1793025240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HCC/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198815","title":"B. Riley Trims Price Target on Warrior Met Coal to $122 From $123, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198815","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678198815?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:54","pubTimestamp":1793015679,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $109.29, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAL","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678619874","title":"Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2678619874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678619874?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:00","pubTimestamp":1793012400,"startTime":"0","endTime":"0","summary":"Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/26/3387977/0/en/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoson-at-esmo-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","HCC","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676020664","title":"Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2676020664","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676020664?lang=en_us&edition=fundamental","pubTime":"2026-10-20 18:18","pubTimestamp":1792491480,"startTime":"0","endTime":"0","summary":"Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated DiseaseNANJING, China, Oct.  20, 2026 (GLOBE NEWSWIRE) -- Nanjing Lea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/20/3384186/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-advances-to-expansion-stage-in-phase-ii-first-line-gastric-cancer-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC","BFJL","CBTY","CBOY","DFII","BTCL","CPS","HODL","CBTA","GBTC","CBOJ","SBIT","MAXI","BITO","BTF","CBOA","IBIT","BPI","BETH","BRRR","QBF","BFAP","YBTC","BITX","ODD","BTRN","ARKB","BCCC","BITB","BTCI","CBXA","CBXO","BITI","HCC","COAL","CBTJ","XBTY","OC","BITY","BTCO","PFS","BTCC","EZBC","FBTC","BTCW","BITU","CRC","BAGY","CBOO","XHB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676368156","title":"Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2676368156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676368156?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:42","pubTimestamp":1792417320,"startTime":"0","endTime":"0","summary":"Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and Long-Term Survival Signals Across Immunologically Cold Tumors and Deep, Sustained","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/19/3383535/0/en/leads-biolabs-opamtistomig-and-lbl-034-featured-in-six-abstracts-at-2026-esmo-congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFII","BTCO","CRS","DEFI","BTRN","BITY","BTCW","BTCZ","HODL","ASH","OC","BRRR","ORR","CBXO","MSS","CBXA","CBXJ","MAXI","BETH","BITU","EZBC","HCC","ARKB","ODD","BITO","PYZ","MNRS","BCCC","CBOJ","CBTA","COAL","CBTO","CBTJ","BITX","BITI","XBTY","BFJL","XAR","CBXY","CR","YBTC","BTCI","QBF","CBOA","BTCL","XHB","BTC","FBTC","EMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675563849","title":"Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675563849","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675563849?lang=en_us&edition=fundamental","pubTime":"2026-10-16 12:47","pubTimestamp":1792126020,"startTime":"0","endTime":"0","summary":"Extending the Company's Immunologically Cold Tumor Strategy into Colorectal CancerNANJING, China , Oct.  16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (\"Leads Biolabs\" or the \"Company,\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/16/3382247/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-enrolls-first-patient-in-phase-ib-ii-combination-trial-in-metastatic-colorectal-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XHB","CBTA","CBTJ","CBXA","CBOA","BETH","BTCC","QBF","DFII","BRRR","BTCO","BITX","ARKB","CBOO","CBXO","BITU","PROC","BTRN","CBTO","CBOY","CBXJ","XBTY","BAGY","BFAP","MAXI","BTCI","BTCL","BTCW","IBIT","MSS","YBTC","EZBC","HODL","BETE","BITO","BITY","BITB","OC","BFJL","FBTC","BTF","SBIT","GBTC","HCC","BTC","CBOJ","COAL","ODD","BTCZ","CBTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675053650","title":"How Investors Are Reacting To Warrior Met Coal (HCC) Blue Creek Ramp Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2675053650","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675053650?lang=en_us&edition=fundamental","pubTime":"2026-10-15 22:39","pubTimestamp":1792075194,"startTime":"0","endTime":"0","summary":"Warrior Met Coal reported an ahead-of-schedule, on-budget start up of its Blue Creek longwall in early Q1 2026. This was followed by Q2 2026 record sales volumes of 3.7 million short tons and a 45% production increase, along with a scheduled Q3 2026 results release and investor call on November 4.\nThe Blue Creek ramp up, combined with lower reported cash cost of sales supported by Section 45X tax credits, shows how Warrior Met Coal is shifting from heavy project spending toward higher...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2055000-choice1-card/1789090286455","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2055000-choice1-card/1789090286455"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-hcc/warrior-met-coal/news/how-investors-are-reacting-to-warrior-met-coal-hcc-blue-cree","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-hcc/warrior-met-coal/news/how-investors-are-reacting-to-warrior-met-coal-hcc-blue-cree","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COAL","BK4006","BK4211","HCC","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675278963","title":"Press Release: Warrior Sets Date for Third Quarter 2026 Earnings Announcement and Investor Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2675278963","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675278963?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:31","pubTimestamp":1792009860,"startTime":"0","endTime":"0","summary":"BROOKWOOD, Ala.--(BUSINESS WIRE)--October 14, 2026--Warrior Met Coal, Inc. (\"Warrior\" or NYSE: HCC) today announced that it will hold its third quarter 2026 investor conference call at 4:30 p.m. ET on","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675758322","title":"Warrior Met Coal Publishes Update to Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2675758322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675758322?lang=en_us&edition=fundamental","pubTime":"2026-10-15 04:30","pubTimestamp":1792009849,"startTime":"0","endTime":"0","summary":"Warrior Met Coal Publishes Update to Financial CalendarWarrior Met Coal will release third-quarter 2026 results following the market close on Nov. 4, 2026.An investor conference call is scheduled for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL5Cp4BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674284057","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674284057","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674284057?lang=en_us&edition=fundamental","pubTime":"2026-10-12 09:47","pubTimestamp":1791769620,"startTime":"0","endTime":"0","summary":"Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold TumorsNANJING, China, Oct.  12, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Bi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/12/3378545/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-granted-fda-fast-track-designation-for-first-line-advanced-or-metastatic-biliary-tract-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XHB","NCIQ","BITX","DEFI","BEGS","CBXJ","DFII","GBTC","OOQB","HCC","BTCZ","FBTC","CRPT","BTCL","YBTC","YBIT","BRRR","HODL","BTRN","MAXI","LABU","BITY","BFJL","BETE","BETH","MSBT","AEIS","MNRS","BTCW","COAL","BTGD","BCCC","QBF","OC","CBTJ","ARKY","SBIT","BTFX","BTF","CBXY","ODD","CBOJ","IBIT","STCE","BFAP","ORR","BAGY","BTC","BITB","BTCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882394","title":"RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882394","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882394?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510439,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Sam Crittenden maintained a Hold rating on Warrior Met Coal on October 7 and set a price target of $110.00. The company’s share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-warrior-met-coal-hcc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-warrior-met-coal-hcc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674097670","title":"Warrior Met Coal is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674097670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674097670?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:33","pubTimestamp":1791477180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HCC/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","HCC","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673900335","title":"UBS Adjusts Price Target on Warrior Met Coal to $102 From $98, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2673900335","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673900335?lang=en_us&edition=fundamental","pubTime":"2026-10-08 22:03","pubTimestamp":1791468184,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $110, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAL","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":-0.0238},{"period":"3month","weight":0.0826},{"period":"6month","weight":-0.0027},{"period":"1year","weight":0.3341},{"period":"ytd","weight":-0.025}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.047428},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.016436},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.028693},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.010079},{"month":5,"riseRate":0.5,"avgChangeRate":0.016174},{"month":6,"riseRate":0.6,"avgChangeRate":-0.005518},{"month":7,"riseRate":0.7,"avgChangeRate":0.066127},{"month":8,"riseRate":0.5,"avgChangeRate":0.054739},{"month":9,"riseRate":0.6,"avgChangeRate":0.012708},{"month":10,"riseRate":0.5,"avgChangeRate":0.03357},{"month":11,"riseRate":0.666667,"avgChangeRate":0.081356},{"month":12,"riseRate":0.777778,"avgChangeRate":0.058477}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction